Core Viewpoint - The article discusses the phenomenon of "fat memory," highlighting that the body retains cellular changes from obesity even after significant weight loss, making it easier to regain weight [8][12][18]. Group 1: Research Findings - A study from the Swiss Federal Institute of Technology analyzed fat tissue from successful weight loss participants, revealing that transcriptional changes induced by obesity persist even two years post-weight loss [9][12]. - In mouse experiments, previously obese mice showed a heightened ability to absorb sugars and fats, leading to faster weight regain when reintroduced to a high-fat diet compared to never-obese mice [8][19]. - The study found that 57-62% of downregulated and 68-75% of upregulated differentially expressed genes (DEGs) post-weight loss could be explained by epigenetic mechanisms [18]. Group 2: Implications of "Fat Memory" - The presence of "fat memory" suggests that individuals who have been obese may face increased difficulty in maintaining weight loss, as their bodies are predisposed to regain weight more rapidly [20][21]. - The research indicates that the duration of obesity may correlate with the severity of "fat memory," with longer periods of obesity leading to more pronounced cellular changes that resist normalization post-weight loss [16][18].

Core Viewpoint - The article emphasizes the importance of a national initiative for weight management in response to the "Healthy China 2030" strategy, aiming to enhance public awareness and skills in weight management while reducing obesity rates by 10% annually by 2026 [19]. Group 1: National Weight Management Initiative - The National Health Commission of China has launched a three-year action plan for "Weight Management Year," targeting significant improvements in public awareness and skills related to weight management by 2026 [19]. - The initiative aims to establish a supportive environment for weight management by 2030, promoting healthy lifestyles and reducing the upward trend of overweight and obesity in the population [19]. Group 2: Effective Weight Loss Methods - The article outlines five effective weight loss methods, including having a nutritious breakfast to boost metabolism, which can help control calorie intake throughout the day [6]. - Drinking plenty of water and avoiding sugary drinks can help reduce appetite and promote metabolism, with a recommendation of at least 2 liters of water daily [8]. - Eating until 80% full can effectively control total calorie intake, and slowing down the eating process can help recognize satiety signals [9]. - Having an early dinner and avoiding food before bedtime can prevent fat accumulation, allowing for better digestion and weight loss [10]. - Controlling the portion of staple foods is crucial; replacing refined carbohydrates with whole grains can stabilize blood sugar levels and enhance weight loss [11].

整理 | GLP1减重宝典内容团队 当国际巨头在短短数年内把减肥药变成"千亿美金"赛道，中国市场却仍处于起步阶段——渗透率不到1%。在诺和诺德和礼来两大外资 寡头加速推进多靶点与口服剂型的同时，国内一批企业凭借差异化策略发起追赶。全球研发进入"下半场"，技术迭代、成本和政策将决 定下一轮胜负。 ▍双寡头的实力与节奏：销售、临床、口服化三条战线同时推进 按国际研究机构估算，全球GLP-1/减肥药市场在未来数年仍将保持高速增长，且口服剂型与适应症扩展（如MAFLD、OSA等）会进一 步放大市场规模。与此同时，中国庞大的超重/肥胖人口代表着巨大的未被满足需求：现阶段中国肥胖/减重药物的处方渗透率远低于美 国（美国肥胖人群用药率已接近两位数），中国市场仍处于"从0到1"的放量窗口期。多家机构与咨询报告预计，中国GLP-1市场在2030 年前后将迎来数十亿至数百亿人民币规模的增长。 诺和诺德与礼来已经把GLP-1从糖尿病药拓展为肥胖管理的核心工具。2025年前三季度，诺和诺德司美格鲁肽组合实现了数十亿美元级 别的销售，成为公司收入主力；礼来凭借替尔泊肽实现了更高增速，季度及累计业绩显著上扬。两家的临床与商业节奏互为推动 ...

Core Viewpoint - The article emphasizes the importance of weight management as a national strategy under the "Healthy China 2030" initiative, highlighting the launch of a three-year action plan to enhance public awareness and capabilities in weight management, aiming to prevent and control obesity [6][7][26]. Group 1: National Initiatives - In 2016, the "Healthy China 2030" plan included obesity prevention as a national strategy, with recent policies encouraging public engagement in weight management [6]. - The National Health Commission (NHC) announced the official start of the three-year "Weight Management Year" action plan during the 2024 National People's Congress, aiming to promote healthy lifestyles and strengthen chronic disease prevention [7][26]. - By 2026, the goal is to significantly enhance public awareness and skills in weight management, with an annual reduction of 10% in obesity rates [26]. Group 2: AI in Weight Management - AI is transforming weight management from an "experience-driven" approach to a "data-driven" one, allowing for more precise weight loss strategies through data analysis [9]. - AI applications in dietary management include personalized meal recommendations and intelligent calorie recognition, with tools like CaloScanAI analyzing food images to provide nutritional reports [10]. - In fitness, AI-driven systems can identify incorrect exercise postures and create personalized training plans, enhancing workout efficiency [10][11]. Group 3: Challenges and Limitations of AI - Despite its advantages, AI in weight management has limitations, such as insufficient real-time interaction with users, which can lead to ineffective adherence to plans [13][14]. - Users may struggle with overly restrictive diets or intense exercise regimens suggested by AI, highlighting the need for human trainers to provide support and adjustments based on individual responses [14]. Group 4: Future Directions for AI in Weight Management - The future of AI in weight management will focus on improving data collection and analysis capabilities, integrating wearable devices with fitness platforms for better user insights [16]. - Enhancements in AI interaction will aim to provide emotional support and motivation, moving beyond basic Q&A to a more engaging user experience [17]. - The shift in weight management philosophy from treating obesity to preventing it is expected, with AI playing a crucial role in personalized interventions and comprehensive health management solutions [17][18].

Core Viewpoint - The article emphasizes the benefits of winter for weight loss, highlighting how the body's metabolism increases during colder months, making it an ideal time for effective fat burning and weight management [5][6][7]. Group 1: Metabolic Changes in Winter - The body's basal metabolic rate naturally rises in winter due to the need to maintain body temperature, leading to increased energy expenditure during exercise [6]. - Fat synthesis slows down in colder temperatures, promoting the breakdown of brown fat for heat, which aids in burning stubborn white fat when combined with scientific exercise methods [7]. Group 2: Exercise and Endurance - The cooler climate in winter makes outdoor aerobic activities like running or hiking more comfortable, allowing individuals to enjoy their workouts and more easily push their endurance limits [8]. Group 3: Key Points for Effective Winter Weight Loss - **Dietary Balance**: It is recommended to avoid high-calorie, greasy foods and instead focus on high-protein, fiber-rich warm foods such as chicken, fish, beef, legumes, root vegetables, and hot soups to maintain satiety and warmth [10]. - **Consistency in Exercise**: Regular indoor and outdoor workouts, whether jogging, skipping rope, or home exercises, are crucial for achieving desired fat loss results [11]. - **Hydration**: Despite reduced thirst perception in winter, maintaining adequate hydration (1.5-2 liters of warm water daily) is essential for effective metabolism [12]. - **Quality Sleep**: Ensuring 7-8 hours of quality sleep helps maintain leptin levels, which suppress appetite, thus supporting weight loss efforts [14]. Group 4: Motivation for Winter Weight Loss - The article encourages individuals not to let cold weather be an excuse for inactivity, urging them to take advantage of the heightened metabolism in winter for greater weight loss results [16].

Core Insights - Recent research indicates that the mechanism of action for GLP-1 medications, such as semaglutide, is more complex than previously thought, as they appear to directly influence metabolism rather than solely suppress appetite [2][4][6]. Group 1: Mechanism of Action - GLP-1 medications were initially believed to primarily promote a feeling of fullness, leading to reduced food intake [3]. - A recent clinical trial showed that participants who took GLP-1 for 24 weeks not only lost weight but also experienced an increase in metabolic rate [4][10]. - The study found that the more weight participants lost, the greater the impact on their metabolism, particularly benefiting those with initially slower metabolic rates [5][12]. Group 2: Implications for Obesity Treatment - The research led by Professor Donal O'Shea suggests that the understanding of obesity treatment is evolving, indicating that it is more complex than simply eating less and exercising more [6][12]. - The findings provide scientific evidence that obesity treatment involves more than just lifestyle changes, highlighting the need for a deeper understanding of how these medications work [6][12]. Group 3: Characteristics of GLP-1 Medications - GLP-1 analogs are widely used for weight loss and were originally developed for treating type 2 diabetes due to their ability to improve insulin response to dietary sugars [8]. - These medications interact with satiety hormones, slowing digestion and prolonging feelings of fullness, but they also have side effects such as nausea and bloating [9]. - The study conducted at St. Vincent's University Hospital involved 30 participants and confirmed that GLP-1 medications also directly affect metabolic activity [9].

Core Insights - The article discusses the health implications of going to bed hungry, highlighting that it can lead to an "energy crisis" in the body, affecting sleep quality and increasing cortisol levels, which may contribute to weight gain [6][7]. Group 1: Health Implications of Hunger - Going to bed hungry can trigger sympathetic nervous system responses, leading to increased heart rate and blood pressure, which negatively impacts sleep quality [6]. - Hunger increases cortisol secretion, a stress hormone that can lead to heightened appetite and fat accumulation, particularly in the abdominal area [6]. Group 2: Consequences of Poor Sleep and Eating Habits - A cycle can develop where hunger leads to poor sleep, resulting in fatigue and increased hunger the next day, which may lead to binge eating and deteriorating health [7]. - Eating late-night snacks, especially high-sugar and high-fat foods, can disrupt deep sleep and cause significant blood sugar fluctuations [9]. Group 3: Recommendations for Healthy Eating Before Sleep - To balance health and sleep, it is suggested to consume light, easily digestible foods if hungry, such as warm milk, unsweetened yogurt, oatmeal, bananas, or almonds [10]. - It is recommended to finish eating 1 to 2 hours before bedtime, with a portion size of 100-150 kilocalories to alleviate hunger without burdening the body or sleep [10].

Core Insights - The article highlights the clinical development of ASC37, a novel oral GLP-1R/GIPR/GCGR triagonist peptide by Gilead Sciences, showcasing its significant pharmacokinetic advantages over existing treatments [5][7]. Group 1: Drug Development - ASC37 has entered clinical development as of November 30, with a notable oral bioavailability of 4.2%, which is approximately 9 times, 30 times, and 60 times higher than semaglutide, tirzepatide, and retatrutide, respectively [5]. - The drug's development leverages Gilead's two core technology platforms: AI-assisted drug discovery and enhanced oral peptide delivery technology [5]. - In non-human primate studies, ASC37 demonstrated an average apparent half-life of about 56 hours, supporting once-daily or even less frequent dosing [7]. Group 2: Efficacy and Exposure - ASC37 exhibited a drug exposure level (measured by area under the curve) approximately 57 times greater than that of retatrutide, indicating a higher amount of active substance entering systemic circulation for enhanced efficacy [7]. - The drug's activity levels in activating GLP-1R, GIPR, and GCGR receptors were approximately 5 times, 4 times, and 4 times higher than retatrutide, respectively [5]. Group 3: Regulatory Plans - Gilead plans to submit a new drug clinical trial application for ASC37 to the FDA for obesity treatment in the second quarter of 2026 [7].

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 2025年4月，国家卫生健康委携手国家中医药局联合发布《关于做好健康体重管理门诊设置与管理工作的通知》，明确要求国家及省级综合医 院、儿童医院和中医医院，须在2025年6月底前基本实现体重管理门诊的全面覆盖。 这一政策的出台，正式拉开了全国医院体系体重管理门诊建设的序幕，充分展现了国家对日益严峻的超重与肥胖问题所采取的积极应对之策。 | 首页 | 工作动态 | 政策文件 | 关于我们 | 返回主站 > | | --- | --- | --- | --- | --- | | 政策文件 | | | | Q 影现在所在位置: 首页>欧贸文件 | | | 关于做好健康体重管理门诊设置与管理工作的通知 | | | | | | 发布时间：2025-04-11 来源: 西政司 | | | A A B | | | | | | 国卫办医政函(2025) 113号 | 肥胖困境：体重异常已经成为国民健康的重大隐患 目前，我国体重异常问题已演变为影响广泛的重大公共健康挑战。 ...

整理 | GLP1减重宝典内容团队 ▍礼来：新晋"减肥药之王"的崛起 2025年第三季度，礼来报告替尔泊肽（糖尿病用Mounjaro＋肥胖症用Zepbound）季度销售额突破100亿美元，进入全球最畅销药物之 列。截至2025年9月，礼来在美国GLP-1药物处方份额达到58%，诺和诺德为42%。替尔泊肽因显著优于司美格鲁肽的减重幅度与代谢 改善效果，被视为"下一代减肥药"的代表。 过去几年，GLP-1受体激动剂的代表药物——诺和诺德的司美格鲁肽（Ozempic/Wegovy）掀起全球减肥与糖尿病治疗热潮，推动公司 成 为 欧 洲 市 值 最 高 的 医 药 企 业 之 一 。 然 而 随 着 礼 来 的 加 入 ， 行 业 格 局 迅 速 变 化 。 礼 来 的 双 靶 点 激 动 剂 替 尔 泊 肽 （Mounjaro/Zepbound）凭借更强的控糖与减重效果正在快速蚕食市场份额。在此背景下，诺和诺德股价近期出现明显回落，而礼来 则迎来新一轮估值上升。 ▍诺和诺德：昔日霸主的滑落 截至2025年底，诺和诺德股价显著下行，单日跌幅曾超过9%–12%。核心原因是其旗舰减肥与糖尿病药物需求不及预期，同时公司下 ...